Elizabeth A. Sweeny

Elizabeth A. Sweeny

Auto-generated profile, based on publicly available information

Elizabeth A. Sweeny

Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Cell
Verified
Journal Article
Closed access
LGLin Guo
Lin Guo
HKHong Joo Kim
Hong Joo Kim
HWHejia Wang
Hejia Wang
JMJohn Monaghan
John Monaghan
FFFernande Freyermuth
Fernande Freyermuth
JSJames Shorter
James Shorter

21 July 2017 in Science
Verified
Journal Article
Closed access
PDF file
SGStephanie N. Gates
Stephanie N. Gates
AYAdam L. Yokom
Adam L. Yokom
JLJiaBei Lin
JiaBei Lin
J Meredith Jackrel
Meredith Jackrel
ARAlexandrea N. Rizo
Alexandrea N. Rizo
DSDaniel R. Southworth
Daniel R. Southworth
Untangling aggregates one step at a time: Conserved AAA+ protein complexes exploit adenosine triphosphate hydrolysis to unfold and disaggregate their substrates in response to cell stress, but exactly how they do this has been unclear. Gates et al. determined high-resolution cryo-electron microscopy structures of the Hsp104 disaggregase bound to an unfolded polypeptide substrate in its channel. The structures reveal substrate interactions and two different translocation states. Hsp104 undergoes conformational changes that drive movement along the substrate by two-amino-acid steps. These states help explain how this molecular machine can solubilize protein aggregates and amyloids. Science , this issue p. 273

1 November 2012 in Cell
Verified
Journal Article
Closed access
MDMorgan E. DeSantis
Morgan E. DeSantis
ELEunice H. Leung
Eunice H. Leung
ESElizabeth A. Sweeny
Elizabeth A. Sweeny
J Meredith Jackrel
Meredith Jackrel
MCMimi Cushman-Nick
Mimi Cushman-Nick
JSJames Shorter
James Shorter

1 September 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ESElizabeth A. Sweeny
Elizabeth A. Sweeny
ASAnuradha Bharara Singh
Anuradha Bharara Singh
Ritu ChakravartiRitu Chakravarti
Ritu Chakravarti
OMOsiris Martinez-Guzman
Osiris Martinez-Guzman
ASArushi Saini
Arushi Saini
DSDennis J. Stuehr
Dennis J. Stuehr
Cellular heme is thought to be distributed between a pool of sequestered heme that is tightly bound within hemeproteins and a labile heme pool required for signaling and transfer into proteins. A heme chaperone that can hold and allocate labile heme within cells has long been proposed but never been identified. Here, we show that the glycolytic protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH) fulfills this role by acting as an essential repository and allocator of bioavailable heme to downstream protein targets. We identified a conserved histidine in GAPDH that is needed for its robust heme binding both in vitro and in mammalian cells. Substitution of this histidine, and the consequent decreases in GAPDH heme binding, antagonized heme delivery to both cytosolic and nuclear hemeprotein targets, including inducible nitric-oxide synthase (iNOS) in murine macrophages and the nuclear transcription factor Hap1 in yeast, even though this GAPDH variant caused cellular levels of labile heme to rise dramatically. We conclude that by virtue of its heme-binding property, GAPDH binds and chaperones labile heme to create a heme pool that is bioavailable to downstream proteins. Our finding solves a fundamental question in cell biology and provides a new foundation for exploring heme homeostasis in health and disease.

1 November 2009 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
BRBlake E Roberts
Blake E Roberts
MDMartin L Duennwald
Martin L Duennwald
HWHuan Wang
Huan Wang
CCChan Chung
Chan Chung
NLNicholas P Lopreiato
Nicholas P Lopreiato
JSJames Shorter
James Shorter
Safely eradicating prions, amyloids and preamyloid oligomers may ameliorate several fatal neurodegenerative disorders. Yet whether small-molecule drugs can directly antagonize the entire spectrum of distinct amyloid structures or 'strains' that underlie distinct disease states is unclear. Here, we investigated this issue using the yeast prion protein Sup35. We have established how epigallocatechin-3-gallate (EGCG) blocks synthetic Sup35 prionogenesis, eliminates preformed Sup35 prions and disrupts inter- and intramolecular prion contacts. Unexpectedly, these direct activities were strain selective, altered the repertoire of accessible infectious forms and facilitated emergence of a new prion strain that configured original, EGCG-resistant intermolecular contacts. In vivo, EGCG cured and prevented induction of susceptible, but not resistant strains, and elicited switching from susceptible to resistant forms. Importantly, 4,5-bis-(4-methoxyanilino)phthalimide directly antagonized EGCG-resistant prions and synergized with EGCG to eliminate diverse Sup35 prion strains. Thus, synergistic small-molecule combinations that directly eradicate complete strain repertoires likely hold considerable therapeutic potential.

1 March 2015 in Molecular Cell
Verified
Journal Article
Closed access
ESElizabeth A. Sweeny
Elizabeth A. Sweeny
J Meredith Jackrel
Meredith Jackrel
MGMichelle S. Go
Michelle S. Go
MSMatthew A. Sochor
Matthew A. Sochor
BRBeatrice M. Razzo
Beatrice M. Razzo
JSJames Shorter
James Shorter